Minerva Surgical today said it closed the acquisition of Boston Scientific’s intrauterine health franchise. The financial details of the deal were not disclosed.
The new combination of devices includes the Minerva Endometrial Ablation System and the Genesys HTA Endometrial Ablation System for visualization in the uterine cavity during treatment. The deal also includes the Symphion tissue removal system, which allows physicians to remove uterine fibroids, and the Resectr device for removing endometrial polyps.
“We are proud to have a complete product line to meet the needs of patients, whether treated in the physician’s office, ambulatory surgery center, or hospital setting,” Minerva Surgical chief medical officer Eugene Skalnyi said in a news release. “The more effectively we treat the conditions that cause AUB, the more likely we are to achieve the objective of lowering the rate of hysterectomies for benign conditions, preserving the patient’s uterus, and positively impacting the patient’s quality of life and cost of care.”
Approximately 400,000 women have hysterectomies per year in the U.S., according to Minerva Surgical. At least 80,000 of those procedures could be unnecessary or avoided.
“Minerva is now AUB’s (abnormal uterine bleeding) worst nightmare,” president and CEO Dave Clapper said. “We are excited to do our part to eliminate this horrible condition that too often results in unnecessary hysterectomies.”
